Advertisement

The History of Psychedelics in Medicine

  • Ben Sessa
Living reference work entry
Part of the Springer Reference Psychologie book series (SRP)

Abstract

Psychedelics have been used for hundreds if not thousands of years by humans. Medical research began in earnest in the West in the late nineteenth century with the discovery of mescaline. From there we saw the development of LSD in the 1940s and an increasingly important role played by psychedelics in the 1950s in the subsequent development of biological psychiatry. Psychiatry explored psychedelic therapies extensively through to the end of the 1960s when LSD was banned. Then, other drugs emerged, notably MDMA, which took abroadly similar path to LSD; being banned in the mid-1980s. However, since then, whilst the debate around recreational uses of drugs continues, there has been a resurgence of psychedelic research in the last two decades. We now see many hundreds of new publications coming from mainstream institutions around the world studying psychedelic drugs. The history of the development of psychedelics in medicine is intimately tied-in with societal, technological and cultural changes and continues to evolve.

Keywords

LSD Psilocybin MDMA Mescaline Psychotherapy Medicine Psychiatry 

Notes

Acknowledgements

Tremendous thanks goes to those friends and colleagues who have offered their kind words in the early development of this article, including George Greer, Rick Doblin, David Nichols, Richard Yensen, Charles Grob, Thomas Roberts, Neal Goldsmith, Andy Roberts and Jay H. Ellens.

References

  1. Angrist, B. M., Sathananthan, G., Wilk, S., & Gershon, S. (1974). Amphetamine psychosis: Behavioural and biochemical aspects. Journal of Psychiatric Research, 11, 13–23.PubMedCrossRefGoogle Scholar
  2. Beringer, K. (1927). Der Meskalinrausch: Seine Geschichte Und Erscheinungsweise (pp. 42, 147). Berlin: Julius Springer.Google Scholar
  3. Blumenfield, M., & Glickman, L. (1967). Ten month’s experience with LSD users admitted to county psychiatric receiving hospital. New York State Journal of Medicine, 67, 1849–1853.PubMedGoogle Scholar
  4. Bogenschutz, M. P., & Pommy, J. A. (2012). Re-examining the therapeutic potential of classical hallucinogens in the treatment of addictions. Drug Testing and Analysis Drug Testing and Analysis, 4(7–8), 543–555.PubMedCrossRefGoogle Scholar
  5. Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. Journal of Psychopharmacology, 29(3), 289–299.PubMedCrossRefGoogle Scholar
  6. Bowdle, T. A., Radant, A. D., Cowley, D. S., Kharash, E. D., Strassman, R. J., & Roy-Byrne, P. P. (1998). Psychedelic effects of ketamine in healthy volunteers. Anesthesiology, 88, 82–88.PubMedCrossRefGoogle Scholar
  7. Bowen, W. T., Soskin, R. A., & Chotlos, J. W. (1970). Lysergic acid diethylamide as a variable in the hospital treatment of alcoholism: A follow-up study. The Journal of Nervous and Mental Disease, 150, 111–118.PubMedCrossRefGoogle Scholar
  8. Breakey, W., et al. (1974). Halluconogenic drugs as precipitants of schizophrenia. Psychological Medicine, 4(03), 255–261.PubMedCrossRefGoogle Scholar
  9. Brown, E. (2002, September 10). Professor X. Wired, p. 9.Google Scholar
  10. Buckman, J., & Ling, T. (1963). Lysergic acid (Lsd 25) & ritalin the treatment of neurosis. London: Lambarde Press.Google Scholar
  11. Buffum, J., & Moser, C. (1986). MDMA and human sexual function. Journal of Psychoactive Drugs, 18, 355–359.PubMedCrossRefGoogle Scholar
  12. Burroughs, W., & Ginsberg, A. (1963). The yage letters. San Francisco: City Lights Books.Google Scholar
  13. Carey, J. (March 1997). Recreational drug wars: Alcohol versus ecstasy – Referenced from the book ‘Ecstasy Reconsidered’ by Nicholas Saunders, 1997.Google Scholar
  14. Carhart-Harris, R. L., Williams, T. M., Sessa, B., et al. (2010). The administration of psilocybin to healthy, hallucinogen-experienced volunteers in a mock-functional magnetic resonance imaging environment: A preliminary investigation of tolerability. Journal of Psychopharmacology, 25(11), 1562–1567. 2011 Nov.PubMedCrossRefGoogle Scholar
  15. Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Read, L. J., Colasanti, A., et al. (2012a). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences, 109(6), 2138–2143.CrossRefGoogle Scholar
  16. Carhart-Harris, R., et al. (2012b). Implications for psychedelic-assisted psychotherapy: Functional magnetic resonance imaging study with psilocybin. The British Journal of Psychiatry, 200, 238–244.PubMedCrossRefGoogle Scholar
  17. Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., Leech, R., Williams, L. T., Williams, T. M., Bolstridge, M., Sessa, B., McGonigle, J., Sereno, M. I., Nichols, D., Hellyer, P. J., Hobden, P., Evans, J., Singh, K. D., Wise, R. G., Curran, H. V., Feilding, A., & Nutt, D. J. (2016a). Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proceedings of the National Academy of Sciences of the United States of America, 113(17), 4853–4858.PubMedPubMedCentralCrossRefGoogle Scholar
  18. Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016b). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry. doi:10.1016/S2215-0366(16)30065-7.Google Scholar
  19. Chabrol, H., & Oehen, P. (2013). MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder. Journal of Psychopharmacology, 27(9), 865–866.PubMedCrossRefGoogle Scholar
  20. Chambers, T. (2014). Editor’s introduction: Psychedelic resurgence – Research and therapeutic uses, past and present. Journal of Psychoactive Drugs, 46(1), 1.PubMedCrossRefGoogle Scholar
  21. Chandler, A. L., & Hartman, M. A. (1960). Lysergic acid diethylamide (LSD-25) as a facilitating agent in psychotherapy. Archives of General Psychiatry, 2(3), 286–299.CrossRefGoogle Scholar
  22. Chwelos, N., Blewett, D. C., Smith, C., & Hoffer, A. (1959). Use of D-lysergic diethylamide in the treatment of alcoholism. Quarterly Journal of Studies of Alcohol, 20, 577–590.Google Scholar
  23. Cohen, S. (1960). Lysergic acid diethylaminde: Side effects and complications. Journal of Nervous and Mental Disorders, 130, 30–40.CrossRefGoogle Scholar
  24. Cohen, S. (1965). The beyond within. New York: Atheneum.Google Scholar
  25. Cohen, S., & Eisner, B. G. (1959). Use of lysergic acid diethylamide in a psychotherapeutic setting. Archives of Neurology and Psychiatry, 81(5), 615–619.PubMedCrossRefGoogle Scholar
  26. Cohen, S., Fichman, L., & Eisner, B. G. (1958). Subjective reports of lysergic acid experiences in a context of psychological test performance. The American Journal of Psychiatry, 115, 30–35.PubMedCrossRefGoogle Scholar
  27. Cohen, M. M., Marinello, M. J., & Back, N. (1967). Chromosomal damage in human leukocytes induced by lysergic acid diethylamide. Science, 155, 1417–1419.PubMedCrossRefGoogle Scholar
  28. Cole, J. (2014). MDMA and the “ecstasy paradigm”. Journal of Psychoactive Drugs, 46(1), 44–56.PubMedCrossRefGoogle Scholar
  29. Condrau, G. (1949). Clinical experience in mental patients with lysergic acid diethylamide. Acta Psychiatrica et Neurologica, 24, 9.CrossRefGoogle Scholar
  30. Correll, G. E., & Futter, G. E. (2006). Two case studies of patients with major depressive disorder given low-dose (subanesthetic) ketamine infusions. Pain Medicine, 7(1), 92–95.PubMedCrossRefGoogle Scholar
  31. Coutinho, T. (2006). From religious ecstasy to ecstasy pills: A symbolic and performative analysis of electronic music festivals. Religião & Sociedade, 2(se), 135–157. Rio de Janeiro.Google Scholar
  32. Crockford, R. M. (2007). LSD in prague; a long-term follow-up study. Multidisciplinary Association for Psychedelic Studies Bulletin, XVII(1), 20–22.Google Scholar
  33. Dahlberg, C. C., Mechaneck, R., & Feldstein, S. (1968). LSD research: The impact of lay publicity. The American Journal of Psychiatry, 125(5), 685–689.PubMedCrossRefGoogle Scholar
  34. Dishotsky, N. I., Loughman, W. D., Mogar, R. E., & Lipscomb, W. R. (1971). LSD and genetic damage. Science, 172(3982), 431–440.PubMedCrossRefGoogle Scholar
  35. Ditman, K. S., & Bailey, J. J. (1967). Evaluating LSD as a psychotherapeutic agent. In Abramson, H. (Ed.), The Use of LSD in Psychotherapy and Alcoholism, (pp. 74–80). Bobbs-Merrill, New York, NY.Google Scholar
  36. Dobkin de Rios, M., & Janiger, O. (2003). LSD, spirituality and the creative process (pp. 1–4). Rochester: Park Street Press.Google Scholar
  37. Doblin, R., Greer, G., Holland, J., Jerome, L., Mithoefer, M. C., & Sessa, B. (2014). A reconsideration and response to Parrott AC (2013) Human psychobiology of MDMA or ‘Ecstasy’: An overview of 25 years of empirical research. Human Psychopharmacology, 29(2), 105–108.PubMedCrossRefGoogle Scholar
  38. Eisner, B. (1989). Ecstasy: The MDMA story. Chapter one ‘introducing Adam’ (pp. 1–15). Berkley: Ronin.Google Scholar
  39. Eisner, B. G., & Cohen, S. (1958). Psychotherapy with lysergic acid diethylamide. The Journal of Nervous and Mental Disease, 127, 528.PubMedCrossRefGoogle Scholar
  40. Emerson, A., Ponté, L., & Doblin, R. (2014). History and future of the multidisciplinary association for psychedelic studies (MAPS). Journal of Psychoactive Drugs, 46(1), 27–36.PubMedCrossRefGoogle Scholar
  41. Eyerman, J. (2013). A clinical report of holotropic breathwork in 11,000 psychiatric inpatients in a community hospital setting. Multidisciplinary Association for Psychedelic Studies Bulletin Special Edition, 23(1), 24–27.Google Scholar
  42. Faillace, L. A., Vourlekis, A., & Szara, S. (1970). Hallucinogenic drugs in the treatment of alcoholism: A two year follow-up. Comprehensive Psychiatry, 11, 51–56.PubMedCrossRefGoogle Scholar
  43. Fielding, L. (2011). To live outside the law: Caught by operation Julie. London: Serpent’s Tail.Google Scholar
  44. Frederking, W. (1953). Intoxicant drugs (mescaline and LSD-25) in psychotherapy. The Journal of Nervous and Mental Diseases, 121, 262.CrossRefGoogle Scholar
  45. Frederking, W. (1955). Intoxicant drugs (mescaline and lysergic acid diethylamide) in psychotherapy. The Journal of Nervous and Mental Disease, 121(3), 262–266.PubMedCrossRefGoogle Scholar
  46. Freedman, D. X. (1961). Effects of LSD-25 on brain serotonin. The Journal of Pharmacology and Experimental Therapeutics, 134(2), 160–166.PubMedGoogle Scholar
  47. Freeman, A. (2006). A Daniel come to judgement? Dennett and the revisioning of transpersonal theory. Journal of Consciousness Studies, 13(3), 95–109.Google Scholar
  48. Funkenstein, D. H. (1955). The physiology of fear and anger. Scientific American, 192(5), 74–80.CrossRefGoogle Scholar
  49. Gasser, P. (1995). Psycholytic therapy with MDMA and LSD in Switzerland. Newsletter of the Multidisciplinary Association for Psychedelic Studies MAPS, 5(3), 3–7.Google Scholar
  50. Gouzoulis-Mayfrank, E., Daumann, J., et al. (2000). Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). Journal of Neurology, Neurosurgery, and Psychiatry, 68, 719–725.PubMedCrossRefGoogle Scholar
  51. Graham, J. D. P., & Khalidi, A. I. (1954). The action of D-lysergic acid diethylamide (LSD 25), part 1, general pharmacology. Journal of the Faculty of Medicine (Baghdad), 18(1), 20, Summarized In Bibliography On Psychotomimetics.Google Scholar
  52. Greer, G. (1985). Using MDMA in psychotherapy. Advances: Journal of the Institute for the Advancement of Health, 2(2), 57–59.Google Scholar
  53. Greer, G., & Tolbert, R. (1986). Subjective reports of the effects of MDMA in a clinical setting. Journal of Psychoactive Drugs, 18(4), 319–327.PubMedCrossRefGoogle Scholar
  54. Greer, G., & Tolbert, R. (1990). The therapeutic use of MDMA. In S. J. Peroutka (Ed.), Ecstasy: The clinical, pharmacological and neurotoxicological effects of the drug MDMA (pp. 21–36). Boston: Kluver Academic Publishers.Google Scholar
  55. Greer, G., Grob, C. S., & Halberstadt, A. L. (2014). PTSD symptom reports of patients evaluated for the New Mexico medical cannabis program. Journal of Psychoactive Drugs, 46(1), 73–77.PubMedCrossRefGoogle Scholar
  56. Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006). Psilocybin can occasion mystical experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology, 187, 268–283.PubMedCrossRefGoogle Scholar
  57. Griffiths, R. R., Johnson, M. W., Richards, W. A., McCann, U., & Richards, B. D. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. Journal of Psychopharmacology, 22(6), 621–632.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Grob, C. S., Poland, R. E., Chang, L., & Ernst, T. (1996). Psychobiologic effects of 3,4- methylenedioxymethamphetamine (MDMA) in humans: Methodological considerations and preliminary observations. Behavioural Brain Research, 73, 103–107.PubMedCrossRefGoogle Scholar
  59. Grob, C., Chopra, G. S., Danforth, A. L., Hagerty, M. C., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2010). Pilot study of psilocybin treatment for anxiety in advanced-stage cancer patients [with G.S.]. Archives of General Psychiatry, 68(1), 71–78.PubMedCrossRefGoogle Scholar
  60. Grof, S. (1973). Theoretical and empirical basis of transpersonal psychology and psychotherapy: Observations from LSD research. Journal of Transpersonal Psychology, 5(1), 15–51.Google Scholar
  61. Grof, S. (1980). The effects of LSD on chromosomes, genetic mutation, fetal development and malignancy. Appendix II of LSD psychotherapy. Alameda: Hunter House Publishers.Google Scholar
  62. Grof, S., Halifax, J., & Kuber-Ross, E. (1977). The human encounter with death. New York: E. P. Dutton.Google Scholar
  63. Grof, S., et al. (2008). The past and future of the international transpersonal association. The International Journal of Transpersonal Studies, 27, 55–62.Google Scholar
  64. Hagenbach, D., & Werthmuller, L. (2013). Mystic chemist: The life of Albert Hofmann and his discovery of LSD (p. 61). Santa Fe: Synergetic Press.Google Scholar
  65. Halpern, J. H., Pope, H. G., Sherwood, A. R., Barry, S., Hudson, J. I., & Yurgelun-Todd, D. (2004). Residual neuropsychological effects of illicit 3,4- methelenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Dependency, 75, 135–147.CrossRefGoogle Scholar
  66. Harman, W. W., McKim, R. H., Mogar, R. E., Fadiman, J., & Stolaroff, M. J. (1966). Psychedelic agents in creative problem solving: A pilot study. Psychological Reports, 19, 211–227.PubMedCrossRefGoogle Scholar
  67. Hartigan, F. (2000). Bill W.: A biography of alcoholics anonymous cofounder Bill Wilson. New York: St. Martins Press.Google Scholar
  68. Havelock Ellis, H. (1897). The phenomena of mescal intoxication. The Lancet, 149(3849), 1540–1542, 5.CrossRefGoogle Scholar
  69. Havelock Ellis, H. (1898). Mescal: A new artificial paradise. Reprint by Speculum Mundi Books, 2010.Google Scholar
  70. Heffter, A. (1898). Ueber Pellote. Naunyn-Schmiedebergs. Archiv für Experimentalle Pathologie und Pharmakologie, 40, 385–429.CrossRefGoogle Scholar
  71. Hoffer, A., Osmond, H., & Smythies, J. (1954). Schizophrenia: A new approach. Journal of Mental Science, 100, 29.PubMedGoogle Scholar
  72. Hofmann, A. (1979). LSD: My problem child. Sarasota: Multidisciplinary Association for Psychedelic Studies. Reprint, 2005.Google Scholar
  73. Hofmann, A., Frey, A., Ott, H., Petrzilka, T. H., & Troxler, F. (1958). Konstitutionsaufklärung Und Synthese Von Psilocybin. Experientia, 14(11), 397.PubMedCrossRefGoogle Scholar
  74. Hollister, L. E., Shelton, J., & Krieger, G. (1969). A controlled comparison of lysergic acid diethylamide (LSD) and dextroamphetmine in alcoholics. The American Journal of Psychiatry, 125, 1352–1357.PubMedCrossRefGoogle Scholar
  75. Home Office. (2009). MDMA (‘ecstasy’): A review of its harms and classification under the Misuse of Drugs Act 1971. http://www.erowid.org/chemicals/mdma/mdma_info13.pdf
  76. Huxley, A. (1954). The doors of perception (p. 6). London: Chatto &Windus.Google Scholar
  77. Huxley, L. (1968). This timeless moment. Berkley: Celestial Arts.Google Scholar
  78. Ingrasci, R. (1985). Testimony for MDMA hearing submitted by Richard Ingrasci, M.D., M.P.H. In the matter of MDMA scheduling. Docket no. 84–48. United States Department of Justice, Drug Enforcement Administration.Google Scholar
  79. Iversen, L. (2006). Speed, ecstasy, ritalin: The science of amphetamines (p. 51). Oxford: OUP.Google Scholar
  80. James, W. (1902). The varieties of religious experience: A study in human nature. Being the clifford lectures on natural religion delivered at Edinburgh in 1901–1902. London/Bombay: Longmans, Green, & Co.Google Scholar
  81. Jensen, S. E., & Ramsay, R. (1963). Treatment of chronic alcoholism with lysergic acid diethylamide. Canadian Psychiatric Association Journal, 8, 182–188.PubMedGoogle Scholar
  82. Johnson, F. G. (1969). LSD in the treatment of alcoholism. The American Journal of Psychiatry, 126, 481–487.PubMedCrossRefGoogle Scholar
  83. Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11), 983–992.PubMedPubMedCentralCrossRefGoogle Scholar
  84. Jungaberle, H., Gasser, P., Weinhol, J., & Verres, R. (Eds.). (2008). Therapy with psychoactive substances. Practice and critique of psychotherapy with LSD, psilocybin and MDMA (1st ed.). Bern: Hans Huber, Hogrefe AG.Google Scholar
  85. Kaelen, M., Barrett, F. S., Roseman, L., Lorenz, R., Family, N., Bolstridge, M., Curran, H. V., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2015). LSD enhances the emotional response to music. Psychopharmacology, 232(19), 3607–3614 (2016).PubMedCrossRefGoogle Scholar
  86. Kaelen, M., Roseman, L., Kahan, J., Santos-Ribeiro, A., Orban, C., Lorenz, R., Barrett, F. S., Bolstridge, M., Williams, T., Williams, L., Wall, M. B., Feilding, A., Muthukumaraswamy, S., Nutt, D. J., Carhart-Harris, R. (2016). LSDmodulates music-induced imagery via changes in parahippocampal connectivity. European Neuropsychopharmacology. pii: S0924-977X(16)30016-5. doi:10.1016/j.euroneuro.Google Scholar
  87. Kast, E. (1967). Attenuation of anticipation: A therapeutic use of lysergic acid diethylamide. Psychiatric Quarterly, 41(4), 646–657.PubMedCrossRefGoogle Scholar
  88. Khamsi, R. (2006, August). Ketamine relieves depression within hours. New Scientist.Google Scholar
  89. Klüver, H. (1928). Studies on the eidetic type and on eidetic imagery. Psychology Bulletin, 25, 69–104.CrossRefGoogle Scholar
  90. Krebs, T. S., & Johansen, P. O. (2012). Lysergic acid diethylamide (LSD) for alcoholism: A meta-analysis of randomized controlled trials. Journal of Psychopharmacology. doi:10.1177/0269881112439253.PubMedGoogle Scholar
  91. Krebs, T. S., & Johansen, P.-Ø. (2013). Psychedelics and mental health: A population study. PLoS ONE, 8(8), e63972. doi:10.1371/journal.pone.0063972.PubMedPubMedCentralCrossRefGoogle Scholar
  92. Krupitsky, E. M., & Grinenko, A. Y. (1997). Ketamine psychedelic therapy (KPT): A review of the results of ten years of research. Journal of Psychoactive Drugs, 29(2), 165–183.PubMedCrossRefGoogle Scholar
  93. Kurland, A. A., Unger, S., Shaffer, J. W., & Savage, C. (1967). Psychedelic therapy utilizing LSD in the treatment of the alcoholic patient: A preliminary report. American Journal of Psychiatry, 123(10), 1202–1209.PubMedCrossRefGoogle Scholar
  94. Kurland, A. A., Savage, C., Pahnke, W. N., Grof, S., & Olsson, J. E. (1971). LSD in the treatment of alcoholism. In O. Vinar, Z. Votava, & P. B. Bradley (Eds.), Advances in neuropsychopharmacology: Proceedings of the 7th congress of the collegium international neuropsychopharma cologicum (pp. 361–372). Amsterdam: North-Holland.Google Scholar
  95. Laing, R. D. (1963). The divided self. London: Penguin.Google Scholar
  96. Laing, A. (1997). R.D. Laing: A biography. London: Harper Collins.Google Scholar
  97. Lebedev, A. V., Kaelen, M., Lövdén, M., Nilsson, J., Feilding, A., Nutt, D. J., & Carhart-Harris, R. L. (2016). LSD-induced entropic brain activity predicts subsequent personality change. Human Brain Mapping. doi:10.1002/hbm.23234.PubMedGoogle Scholar
  98. Lee, M. A., Shlain, B. (1992). Acid dreams: The complete social history of LSD (pp. 44–45). Grove Atlantic Press, New York.Google Scholar
  99. Leuner, H. (1962). Experimental psychosis. Its psychopharmacology, phenomenology, and dynamics in relation to personality. Neurologie et Psychiatrie, 95, 1–275.Google Scholar
  100. Lewin, L. (1894). “Über Anhalonium Lewinii Und Andere Cacteen” – On Anhalonium Lewinii And Other Cacti. In Archives of Experimental Pathology and Pharmacology, 34(5–6), December 14, 1894 p 374–391.Google Scholar
  101. Liechti, M. E., & Vollenweider, F. X. (2001). Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Neuropsychobiology, Human Psychopharmacology: Clinical and Experimental, 16, 589–598.CrossRefGoogle Scholar
  102. Liechti, M. E., Gamma, A., & Vollenweider, F. X. (2001). Gender differences in the subjective effects of MDMA. Psychopharmacology, 154, 161–168.PubMedCrossRefGoogle Scholar
  103. Ling, T. M., & Buckman, J. (1963). The treatment of anxiety with lysergic acid and methylphenidate. Practitioner, 191, 201–204.PubMedGoogle Scholar
  104. Loizaga-Velder, A., & Verres, R. (2014). Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence – Qualitative results. Journal of Psychoactive Drugs, 46(1), 63–72.PubMedCrossRefGoogle Scholar
  105. Lotsof, H. S. (1995). Ibogaine in the treatment of chemical dependency disorders. Multidisciplinary Association for Psychedelic Studies Bulletin, 5(3), 16–27.Google Scholar
  106. Ludewig, S., Ludewig, K., Hasler, F., & Vollenweider, F. X. (2003). No lasting effects of moderate doses of MDMA (ecstasy) on memory performance and mood states in healthy humans. Biological Psychiatry, 53(Suppl), 205S.Google Scholar
  107. Ludwig, A. M., Levine, J., & Stark, L. H. (1970). LSD and alcoholism: A clinical study of treatment efficacy. Springfield: Charles C Thomas.Google Scholar
  108. Malleson, N. (1971). Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. The British Journal of Psychiatry, 118(543), 229–230.PubMedCrossRefGoogle Scholar
  109. Martin, J. (1962). The treatment of 12 male homosexuals with LSD. Acta Psychotherapeutica, 10, 395–402.CrossRefGoogle Scholar
  110. Mash, D. C., Kovera, C. G., Buck, B. E., Norenberg, M. D., Shapshak, P., Hearn, W. L., & Sanchez-Ramos, J. (1998). Medication development of ibogaine as a pharmacotherapy for drug dependence. Annals of the New York Academy of Sciences, 844, 274–292.PubMedCrossRefGoogle Scholar
  111. McLean, J. R., MacDonald, D. C., Byrne, U. P., & Hubbard, A. M. (1961). The use of LSD-25 in the treatment of alcoholism and other psychiatric problems. Quarterly Journal of Studies on Alcohol, 22, 3445.Google Scholar
  112. McLellan, A. T., Woody, G. E., & O’Brien, C. P. (1979). Development of psychiatric illness in drug abusers. Possible role of drug preference. The New England Journal of Medicine, 301, 1310–1314.CrossRefGoogle Scholar
  113. Mithoefer, M. C., Wagner, M. T., Mithoefer, A. T., Jerome, L., & Doblin, R. (2010). The safety and efficacy of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: The first randomized controlled pilot study. Journal of Psychopharmacology, 25(4), 439–452.PubMedCrossRefGoogle Scholar
  114. Mithoefer, M. C., et al. (2013). Durability of improvement in PTSD symptoms and absence of harmful effects or drug dependency after MDM-assisted Psychotherapy: A prospective long-term follow-up study. Journal of Psychopharmacology, 27, 28–39.PubMedPubMedCentralCrossRefGoogle Scholar
  115. Mogar, R. E., & Aldrich, R. W. (1969). The use of psychedelic agents with autistic schizophrenic children. Behavioural Neuropsychiatry, 1(8), 44–50.Google Scholar
  116. Moreno, F. A., & Delgado, P. L. (1997). Hallucinogen-induced relief of obsessions and compulsions [letter]. The American Journal of Psychiatry, 154, 1037–1038.PubMedGoogle Scholar
  117. Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006). Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. The Journal of Clinical Psychiatry, 67, 1735–1740.PubMedCrossRefGoogle Scholar
  118. Morgan, M. J. (2000). Ecstasy (MDMA): A review of its possible persistent psychological effects. Psychopharmacology, 152(3), 230–248.PubMedCrossRefGoogle Scholar
  119. Muthukumaraswamy, S. D., Carhart-Harris, R. L., Moran, R. J., Brookes, M. J., Williams, T. M., Errtizoe, D., Sessa, B., Papadopoulos, A., Bolstridge, M., Singh, K. D., Feilding, A., Friston, K. J., & Nutt, D. J. (2013). Broadband cortical desynchronization underlies the human psychedelic state. The Journal of Neuroscience, 33(38), 15171–15183.PubMedCrossRefGoogle Scholar
  120. Nichols, D. E. (2014). The Heffter research institute: Past and hopeful future. Journal of Psychoactive Drugs, 46(1), 20–26.PubMedCrossRefGoogle Scholar
  121. Nutt, D. J., et al. (2007). The development of a rational scale to assess the harm of drugs of potential misuse. The Lancet, 369, 1047–1053.CrossRefGoogle Scholar
  122. Oehen, P., et al. (2012). A randomized, controlled pilot study of MDMA ({+/−}3,4-Methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). Journal of Psychopharmacology, 27, 40–52.PubMedCrossRefGoogle Scholar
  123. Osmond, O. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Sciences, 66(3), 418–434.PubMedCrossRefGoogle Scholar
  124. Osmond, H., & Smythies, J. (1952). Schizophrenia: A new approach. The Journal of Mental Science, 98, 309–315.PubMedGoogle Scholar
  125. Parrott, A. C. (2014). The potential dangers of using MDMA for psychotherapy. Journal of Psychoactive Drugs, 46(1), 37–43.PubMedCrossRefGoogle Scholar
  126. Passie, T. (1997). Hanscarl Leuner: Pioneer of hallucinogen research and psycholytic therapy. Multidisciplinary Association for Psychedelic Studies, 7(1), 46–49.Google Scholar
  127. Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008). The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience and Therapeutics, 14(4), 295–314.PubMedCrossRefGoogle Scholar
  128. Piper, A. (2013). Leo Perutz and the mystery of St Peter’s snow. Time and Mind: The Journal of Archaeology, Consciousness and Culture, 6(2), 175–198.CrossRefGoogle Scholar
  129. Riba, J. (1998). A pharmacological study of ayahuasca in healthy volunteers. Multidisciplinary Association for Psychedelic Studies Bulletin, 8(3), 12–15.Google Scholar
  130. Riba, J. (2003). Human pharmacology of ayahuasca. TESI doctoral dissertation, Universitat Autonoma de Barcelona.Google Scholar
  131. Riba, J., et al. (2001). Subjective effects and tolerability of the South American psychoactive beverage ayahuasca in healthy volunteers. Psychopharmacology, 154, 85–95.PubMedCrossRefGoogle Scholar
  132. Riba, J., Rodriguez-Fornells, A., & Barbanoj, M. (2002). Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively. Psychopharmacology, 165, 18–28.PubMedCrossRefGoogle Scholar
  133. Ricaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., & McCann, U. D. (2002). Severe dopaminergic neurotoxicity in primates after a common recreational dose regimen of MDMA (“ecstasy”). Science, 297, 2260–2263.PubMedCrossRefGoogle Scholar
  134. Ricaurte, G. A., Yuan, J., Hatzidimitriou, G., Cord, B. J., & McCann, U. D. (2003). Retraction. Science, 301, 1429.CrossRefGoogle Scholar
  135. Rinkel, M., Jackson, D., Hyde, R. W., & Solomon, H. C. (1952). Experimental schizophrenia-like symptoms. The American Journal of Psychiatry, 108, 572–578.PubMedCrossRefGoogle Scholar
  136. Roberts, A. (2008). Albion dreaming: A popular history of LSD in Britain. London: Marshall Cavendish.Google Scholar
  137. Rostafinski, M. (1950). Experimental hallucination in epileptic patients. Rocznik Psychiatryczny (Poland), 38, 109; Summarized In Bibliography On Psychotomimetics, 1943–1966 (U.S. Department Of Health, Education And Welfare, Public Health Service, 1966), P. 5.Google Scholar
  138. Roubicek, J. (1962). Lecebny Vliv Diethylamidu Kyseliny Lysergove (LSD). [Therapeutic effect of lysergic acid diethylamide]. Activitas Nervosa Superior, 4, 240–241.PubMedGoogle Scholar
  139. Rydzynski, Z., Cwynar, S., & Grzelak, L. (1968). Preliminary report on the experience with psychotomimetic drugs in the treatment of alcoholism. Activitas Nervosa Superior (Praha), 10(3), 273.Google Scholar
  140. Sandison, R., & Sessa, B. (2008). An interview with Dr Ronald Sandison – LSD pioneer in UK psychiatry. Multidisciplinary Association for Psychedelic Studies Bulletin, 3, 32–35Google Scholar
  141. Sandison, R. A., Spencer, A. M., & Whitelaw, J. D. (1954). The therapeutic value of LSD in mental illness. The Journal of Mental Science, 100(419), 491–507.PubMedGoogle Scholar
  142. Sarett, M., Cheek, F., & Osmond, H. (1966). Reports of wives of alcoholics of effects of LSD-25 treatment of their husbands. Archives of General Psychiatry, 14(2), 171–178.PubMedCrossRefGoogle Scholar
  143. Schifano, F., Oyefeso, A., Webb, L., Pollard, M., Corkery, J., & Ghodse, A. (2003). Review of deaths related to taking ecstasy, England and Wales, 1997–2000. BMJ [British Medical Journal], 326(7380), 80–81.CrossRefGoogle Scholar
  144. Schultes, R. E, Hofmann, A., & Rätsch, C. (1979). Plants of the gods (pp. 14–48). Inner Traditions. Rochester, Vermont.Google Scholar
  145. Selvaraj, S., et al. (2009). Brain serotonin transporter binding in former users of MDMA (‘ecstasy’). The British Journal of Psychiatry, 194, 355–359.PubMedCrossRefGoogle Scholar
  146. Sessa, B. (2005). Can psychedelics have a role in psychiatry again? British Journal of Psychiatry, 186, 457–459.PubMedCrossRefGoogle Scholar
  147. Sessa, B. (2006). From sacred plants to psychotherapy: The history and re-emergence of psychedelics in medicine. From the 2006 meeting of the Royal College of psychiatry’s spirituality in psychiatry special interest group. Available at http://www.rcpsych.ac.uk/pdf/Ben%20Sessa%20%20From%20Sacred%20Plants%20to%20Psychotherapy.pdf
  148. Sessa, B. (2010). Self-medication of LSD and MDMA to treat mental disorders: A case series. The Journal of Alternative Medicine Research, 2(2), 245–249.Google Scholar
  149. Sessa, B. (2012). Could MDMA be useful in the treatment of PTSD? Progress in Neurology and Psychiatry, 15(6), 4–7, November/December 2011.CrossRefGoogle Scholar
  150. Sessa, B. (2015). Turn on and tune in to evidence based psychedelic research. The Lancet Psychiatry, 2(1), 10–12.PubMedCrossRefGoogle Scholar
  151. Sessa, B., & Grey, A. (2015). Painting of Dr. Alexandra and Ann Shulgin by Alex Grey, with commentary from Sessa and Grey – On the cover of the British Journal of Psychiatry, 206(1), 3.Google Scholar
  152. Sessa, B., & Johnson, M. (2015). Is there a role for psychedelics in the treatment of drug dependency? British Journal of Psychiatry.Google Scholar
  153. Sessa, B., & Meckel Fischer, F. (2015). Underground LSD, MDMA and 2-CB-assisted individual and group psychotherapy in Zurich: Outcomes, implications and commentary. Journal of Independent Scientific Committee on Drugs, 1, 1–8.Google Scholar
  154. Sessa, B., & Nutt, D. J. (2007). MDMA, politics and medical research: Have we thrown the baby out with the bathwater? Journal of Psychopharmacology, 21, 787–791.PubMedCrossRefGoogle Scholar
  155. Sessa, B. (2014) Why psychiatry needs psychedelics and psychedelics need psychiatry. Journal of Psychoactive Drugs, Jan-Mar 46(1): 57–62.Google Scholar
  156. Sessa, B., & Nutt, D. J. (2015). Making a medicine out of MDMA. British Journal of Psychiatry, 206(1), 4–6.PubMedCrossRefGoogle Scholar
  157. Sewell, R. A., Halpern, J. H., & Pope, H. G. (2006). Response of cluster headache to psilocybin and LSD. Journal of Neurology, 66(12), 1920–1922.CrossRefGoogle Scholar
  158. Seymour, R. B., & Wesson, D. R. (Eds.) (1986). Proceedings from: MDMA: A multidisciplinary conference. Journal of Psychoactive Drugs, 18(6), 22–28.Google Scholar
  159. Shulgin, A. (1964). 3-methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature, 201, 1120–1121. 29.PubMedCrossRefGoogle Scholar
  160. Shulgin, A. T., & Nichols, D. E. (1978). Characterization of three new psychotomimetcs. In R. C. Stillman & R. E. Willette (Eds.), The psychopharmacology of hallucinogens. New York: Pergamon Press.Google Scholar
  161. Shulgin, A., & Shulgin, A. (1991). PiHKAL: A chemical love story. Berkeley: Transform Press.Google Scholar
  162. Shulgin, A., & Shulgin, A. (1997). TiHKAL: The continuation. Berkeley: Transform Press.Google Scholar
  163. Smart, R. G., & Bateman, K. (1967). Unfavourable reactions to LSD: A review and analysis of the available case reports [review]. Canadian Medical Association Journal, 97, 1214–1221.PubMedPubMedCentralGoogle Scholar
  164. Smart, R. G., Storm, T., Baker, E. F., & Solursh, L. (1966). A controlled study of lysergide in the treatment of alcoholism. 1. The effects on drinking behavior. Quarterly Journal of Studies on Alcohol, 27(3), 469–482.PubMedGoogle Scholar
  165. Smith, C. (1958). A new adjunct to the treatment of alcoholism: The hallucinogenic drugs. Quarterly Journal of Studies on Alcohol, 19(406), 417.Google Scholar
  166. Smith, D. E., Raswyck, G. E., & Davidson, L. D. (2014). From Hofmann to the Haight Ashbury, and into the future: The past and potential of lysergic acid diethlyamide. Journal of Psychoactive Drugs, 46(1), 3–10.PubMedCrossRefGoogle Scholar
  167. Snelders, S. (1998). The LSD therapy career of Jan Bastiaans, M.D. Newsletter of the Multidisciplinary Association for Psychedelic Studies, 8(1), 18–20.Google Scholar
  168. Snyder, S. H., Banerjee, S. P., Yamamura, H. I., & Greenberg, D. (1974). Drugs, neurotransmitters and schizophrenia. Science, 184(4143), 1243–1253.PubMedCrossRefGoogle Scholar
  169. Späth, E. (1919). Über Die Anhalonium-Alkaloide. I. Anhalin Und Mezcalin. Monatshefte Für Chemie – Chemical Monthly, 40(2), 129–154.CrossRefGoogle Scholar
  170. Stockings, G. T. (1940). A clinical study of the mescaline psychosis, with special reference to the mechanism of the genesis of schizophrenic and other psychotic states. The British Journal of Psychiatry, 86, 29–47.CrossRefGoogle Scholar
  171. Stolaroff, M. (1994). Thanatos to eros, 35 years of psychedelic exploration. Thaneros Publishers. Berlin, Germany.Google Scholar
  172. Stolaroff, M. (1997). The secret chief revealed: Conversations with Leo Zeff, pioneer in the underground psychedelic therapy movement. Sarasota: Multidisciplinary Association for Psychedelic Studies (2004).Google Scholar
  173. Stolaroff, M. J., & Wells, C. W. (1993). Preliminary results with new psychoactive agents 2C-T-2 and 2C-T-7. In Yearbook for ethnomedicine and the study of consciousness (Vol. 2, pp. 99–117). Berlin: VBD – Verlag fur Wissenschaft und Bildung.Google Scholar
  174. Stoll, W. A. (1947). LSD, EinPhantastikumAusDer Mutterkorngruppe. Schweizer Archiv für Neurologie und Psychiatrie, 60, 279.Google Scholar
  175. Strassman, R. J. (1996). Human psychopharmacology of N,N-dimethyltryptamine. Behavioural Brain Research, 73, 121–124.PubMedCrossRefGoogle Scholar
  176. Strassman, R. (2001). DMT: Spirit molecule (pp. 11–40). Rochester: Park Street Press.Google Scholar
  177. Ungerleider, J. T., Fisher, D. D., & Fuller, M. (1966). The dangers of LSD. Analysis of seven months’ experience in a university hospital’s psychiatric service. JAMA, 197, 389–392.PubMedCrossRefGoogle Scholar
  178. Van Dusen, W., Wilson, W., Miners, W., & Hook, H. (1967). Treatment of alcoholism with lysergide. Quarterly Journal of Studies on Alcohol, 28, 295–303.PubMedGoogle Scholar
  179. Vollenweider, F. X. (2002). Brain mechanisms of hallucinogens and entactogens. Dialogues in Clinical Neuroscience, 3(5), 265–279.Google Scholar
  180. Vollenweider, F. X., Liechti, M. E., Gamma, A., Greer, G., & Geyer, M. (2002). Acute psychological and neurophysiological effects of MDMA in humans. Journal of Psychoactive Drugs, 34(2), 171–184.PubMedCrossRefGoogle Scholar
  181. Wasson, R.G. (1957, May 13). Seeking the magic mushroom. Life Magazine.Google Scholar
  182. Weir Mitchell, S. (1896). Remarks on the effects of anheloniumLewinii. The Mescal Button British Medical Journal, 2(1875), 1625–1629.CrossRefGoogle Scholar
  183. Winkler, P., & Csémy, L. (2014). Self-experimentations with psychedelics among mental health professionals: LSD in the former Czechoslovakia. Journal of Psychoactive Drugs, 46(1), 11–19.PubMedCrossRefGoogle Scholar
  184. Zetnik, K. (Yehiel De-Nur) (1989). Bestendig voorogen. Kampen: De paddestoelwolk van Auschwitz.Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland 2016

Authors and Affiliations

  1. 1.Imperial College LondonLondonUK

Personalised recommendations